Patents by Inventor Gabriela Chiosis
Gabriela Chiosis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10421758Abstract: The disclosure relates to novel selective Grp94 inhibitors, compositions comprising an effective amount of such compounds, and methods to treat or prevent a condition, such as cancer, comprising administering to an animal in need thereof an effective amount of such compounds.Type: GrantFiled: August 15, 2014Date of Patent: September 24, 2019Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Gabriela Chiosis, Pengrong Yan, Pallav Patel, Hardik J. Patel, Tony Taldone, Chenghua Yang, Weilin Sun, Stefan O. Ochiana
-
Publication number: 20190241526Abstract: The present invention, among other things, provides compounds and compositions thereof for use in the modulation of Hsp70. In some embodiments, the present invention provides a method for inhibiting Hsp70 activity. In some embodiments, the present invention provides a method of treating a subject suffering from or susceptible to a disease, disorder, or condition responsive to Hsp70 inhibition comprising administering to the subject a therapeutically effective amount of a provided compound. In some embodiments, the present invention provides a method for treating or preventing cancer in a subject suffering therefrom, comprising administering to a patient in need thereof a therapeutically effective amount of a provided compound.Type: ApplicationFiled: November 2, 2018Publication date: August 8, 2019Inventors: Gabriela Chiosis, Yanlong Kang, Hardik J. Patel, Maulik Patel, Stefan Ochiana, Anna Rodina, Tony Taldone, Liza Shrestha
-
Patent number: 10336757Abstract: Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are other wise delivered to the brain.Type: GrantFiled: July 2, 2007Date of Patent: July 2, 2019Assignees: Sloan-Kettering Institute for Cancer Research, The Rockefeller UniversityInventors: Gabriela Chiosis, Paul Greengard, Fei Dou, Wenjie Luo, Huazhong He, Danuta Zatorska
-
Patent number: 10329293Abstract: The present invention provides methods for radiolabeling compounds useful as Hsp90 inhibitors. The present invention also provides intermediates useful in such methods, and compositions of radiolabeled compounds. The present invention provides, among other things novel methods for the synthesis of radiolabeled compounds. In certain embodiments, the present invention provides compounds of formula I.Type: GrantFiled: May 4, 2018Date of Patent: June 25, 2019Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Stefan O. Ochiana, NagaVaraKishore Pillarsetty, Tony Taldone, Gabriela Chiosis
-
Patent number: 10201623Abstract: The present invention provides new methods for cardiac imaging and related medical applications thereof. In some embodiments, the present invention provides a method for the diagnosis of cardiovascular diseases, conditions, or disorders. In some embodiments, the present invention provides a method for the treatment or prevention of cardiovascular diseases, conditions, or disorders. In some embodiments, the present invention provides methods for monitoring the effect of cancer treatment on the heart, and/or methods for monitoring a cancer treatment regimen. In some embodiments, the present invention provides a method for selecting subjects for a test or treatment. In some embodiments, the present invention provides a method for determining the dosage of a drug. In some embodiments, the present invention provides methods for determining the risk of a cardiovascular disease, for assessing risk of a cardiovascular disease, and/or for determining the risk of heart attack.Type: GrantFiled: March 14, 2014Date of Patent: February 12, 2019Assignee: Memorial Sloan Kettering Cancer CenterInventors: Mark Dunphy, H. William Strauss, Gabriela Chiosis
-
Publication number: 20190038626Abstract: The present subject matter relates to a compound represented by the general formula (I) or (I?) or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one of these compounds; methods of making at least one of these compounds; methods of using at least one of these compounds for treating and/or preventing various cancers and/or proliferation disorders; methods of using at least one of these compounds for monitoring the effectiveness of an anticancer therapy against various cancers. In one embodiment, the subject matter relates to compounds that bind with a level of specificity to heat shock protein 70 (Hsp70). In another embodiment, the subject matter relates to compounds that bind with a level of specificity to inhibit both heat shock protein 70 (Hsp70) and heat shock cognate protein 70 (Hsc70).Type: ApplicationFiled: July 17, 2018Publication date: February 7, 2019Inventors: Gabriela Chiosis, Tony Taldone, Anna Rodina, Pallav Patel, Yanlong Kang
-
Publication number: 20190023708Abstract: Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands.Type: ApplicationFiled: May 18, 2018Publication date: January 24, 2019Inventor: Gabriela Chiosis
-
Patent number: 10172863Abstract: The present application provides substituted purine derivatives and related compounds of the formulas shown. These compounds are useful as inhibitors of HSP90, and hence in the treatment of related diseases. (Formulae) Z1-Z3, Xa-Xc, X2, X4, Y and R are as defined in the specification.Type: GrantFiled: April 21, 2016Date of Patent: January 8, 2019Assignee: Sloan-Kettering Institute For Cancer ResearchInventors: Gabriela Chiosis, Tony Taldone, Weilin Sun
-
Patent number: 10167285Abstract: Hsp90 inhibitors havin are provided havin the formula: (I) with a 2?,4?,5?-substitution pattern on the right-side aryl moiety. X1 represents two substituents, which may be the same or different, disposed in the 4? and 5? positions on the aryl group, wherein X1 is selected from halogen, alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, amido, alkylamido dialkylamido, acylamino, alkylsulfonylamido, trihalomethoxy, trihalocarbon, thioalkyl, SO2alkyl, COO-alkyl, KH2, OH, CN, SO2X5, NO2, NO, C?SR2 NSO2X5, C?OR2, where X5 is F, NH2, alkyl or H, and R2 is alkyl, NH2, NH-alkyl or O-alkyl, C1 to C6 alkyl or alkoxy; or wherein X1 has the formula —O—(CH2)n—O—, wherein n is an integer from 0 to 2, preferably 1 or 2, and one of the oxygens is bonded at the 5?-position and the other at the 4?-position of the aryl ring. The compounds are useful in cancer therapy and as radioimaging ligands.Type: GrantFiled: June 13, 2017Date of Patent: January 1, 2019Assignee: Memorial Sloan Kettering Cancer CenterInventors: Gabriela Chiosis, Huazhong He, Laura Llauger-Bufi, Joungnam Kim, Steven M. Larson, Peter Smith-Jones
-
Patent number: 10160729Abstract: The present invention, among other things, provides compounds and compositions thereof for use in the modulation of Hsp70. In some embodiments, the present invention provides a method for inhibiting Hsp70 activity. In some embodiments, the present invention provides a method of treating a subject suffering from or susceptible to a disease, disorder, or condition responsive to Hsp70 inhibition comprising administering to the subject a therapeutically effective amount of a provided compound. In some embodiments, the present invention provides a method for treating or preventing cancer in a subject suffering therefrom, comprising administering to a patient in need thereof a therapeutically effective amount of a provided compound.Type: GrantFiled: December 14, 2017Date of Patent: December 25, 2018Assignee: Memorial Sloan Kettering Cancer CenterInventors: Gabriela Chiosis, Yanlong Kang, Hardik J. Patel, Maulik Patel, Stefan Ochiana, Anna Rodina, Tony Taldone, Liza Shrestha
-
Publication number: 20180280397Abstract: The disclosure provides methods of using inhibitors of chaperone proteins, such as HSP90 inhibitors, in combination with agents that increase proteotoxic stress on tumor cells or agents that induce a biochemical rewiring of the chaperome. The proteotoxic agents are administered prior to administration of the chaperone proteins to achieve synergistic activity.Type: ApplicationFiled: October 5, 2016Publication date: October 4, 2018Inventors: Gabriela Chiosis, Tony Taldone, Liza Shrestha, John Koren, Erica M. Gomes-DaGama, Anna Rodina
-
Publication number: 20180251461Abstract: The present invention provides methods for radiolabeling compounds useful as Hsp90 inhibitors. The present invention also provides intermediates useful in such methods, and compositions of radiolabeled compounds. The present invention provides, among other things novel methods for the synthesis of radiolabeled compounds. In certain embodiments, the present invention provides compounds of formula I.Type: ApplicationFiled: May 4, 2018Publication date: September 6, 2018Inventors: Stefan O. Ochiana, NagaVaraKishore Pillarsetty, Tony Taldone, Gabriela Chiosis
-
Patent number: 10064867Abstract: The disclosure relates to Compounds of Formula (1): and pharmaceutically acceptable salts thereof wherein Z1, Z2, Z3, Xa, Xb, Xc, Y, X2, and X4 are as defined herein, compositions comprising an effective amount of a Compound of Formula (1) or a pharmaceutically acceptable salt thereof, and methods to treat or prevent a condition, such as cancer which overexpresses Her-kinases, comprising administering to an patient in need thereof a therapeutically effective amount of a Compound of Formula (1) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 9, 2016Date of Patent: September 4, 2018Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Tony Taldone, Gabriela Chiosis
-
Patent number: 10052325Abstract: The present subject matter relates to a compound represented by the general formula (I) or (I?) or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one of these compounds; methods of making at least one of these compounds; methods of using at least one of these compounds for treating and/or preventing various cancers and/or proliferation disorders; methods of using at least one of these compounds for monitoring the effectiveness of an anticancer therapy against various cancers. In one embodiment, the subject matter relates to compounds that bind with a level of specificity to heat shock protein 70 (Hsp70). In another embodiment, the subject matter relates to compounds that bind with a level of specificity to inhibit both heat shock protein 70 (Hsp70) and heat shock cognate protein 70 (Hsc70).Type: GrantFiled: August 8, 2016Date of Patent: August 21, 2018Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Gabriela Chiosis, Tony Taldone, Anna Rodina, Pallav Patel, Yanlong Kang
-
Publication number: 20180170883Abstract: The present invention, among other things, provides compounds and compositions thereof for use in the modulation of Hsp70. In some embodiments, the present invention provides a method for inhibiting Hsp70 activity. In some embodiments, the present invention provides a method of treating a subject suffering from or susceptible to a disease, disorder, or condition responsive to Hsp70 inhibition comprising administering to the subject a therapeutically effective amount of a provided compound. In some embodiments, the present invention provides a method for treating or preventing cancer in a subject suffering therefrom, comprising administering to a patient in need thereof a therapeutically effective amount of a provided compound.Type: ApplicationFiled: December 14, 2017Publication date: June 21, 2018Inventors: Gabriela Chiosis, Yanlong Kang, Hardik J. Patel, Maulik Patel, Stefan Ochiana, Anna Rodina, Tony Taldone, Liza Shrestha
-
Patent number: 10000494Abstract: Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands.Type: GrantFiled: July 25, 2016Date of Patent: June 19, 2018Assignee: Sloan-Kettering Institute for Cancer ResearchInventor: Gabriela Chiosis
-
Patent number: 9994573Abstract: The present invention provides methods for radiolabeling compounds useful as Hsp90 inhibitors. The present invention also provides intermediates useful in such methods, and compositions of radiolabeled compounds. The present invention provides, among other things, novel methods for the synthesis of radiolabeled compounds. In certain embodiments, the present invention provides compounds of formula I.Type: GrantFiled: December 23, 2014Date of Patent: June 12, 2018Assignee: Memorial Sloan-Kettering Cancer CenterInventors: Stefan O. Ochiana, NagaVaraKishore Pillarsetty, Tony Taldone, Gabriela Chiosis
-
Patent number: 9926321Abstract: The disclosure relates to Compounds of Formulae (IA) and (IB), and pharmaceutically acceptable salts thereof wherein Z1, Z2, Z3, Xa, Xb, Xc, Xd, Y, X2, and X4 are as defined herein, compositions comprising an effective amount of a Compound of Formula (IA) and/or (IB), and methods to treat or prevent a condition, such cancer which overexpresses Her-kinases, comprising administering to an patient in need thereof a therapeutically effective amount of a Compound of Formula (IA) or (IB). The disclosure further relates to compounds of Formulae (IA) and (IB) in which X2 is a leaving for introducing a radiolabeled atom, such as 124I or 131I and to methods of using such compounds in the preparation of radiolabeled compounds, particularly for use in imaging.Type: GrantFiled: May 20, 2016Date of Patent: March 27, 2018Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Weilin Sun, Tony Taldone, Pallav Patel, Gabriela Chiosis
-
Patent number: 9878987Abstract: The present invention provides compounds I and II and compositions thereof for use in the modulation of Hsp70. In some embodiments, the present invention provides a method for inhibiting Hsp70 activity. In some embodiments, the present invention provides a method of treating a subject suffering from or susceptible to a disease, disorder, or condition responsive to Hsp70 inhibition comprising administering to the subject a therapeutically effective amount of a provided compound. In some embodiments, the present invention provides a method for treating or preventing cancer in a subject suffering therefrom, comprising administering to a patient in need thereof a therapeutically effective amount of a provided compound.Type: GrantFiled: May 13, 2015Date of Patent: January 30, 2018Assignee: Memorial Sloan Kettering Cancer CenterInventors: Gabriela Chiosis, Yanlong Kang, Hardik J. Patel, Maulik Patel, Stefan Ochiana, Anna Rodina, Tony Taldone, Liza Shrestha
-
Publication number: 20170342073Abstract: Hsp90 inhibitors havin are rovided havin the formula: (I) with a 2?,4?,5?-substitution pattern on the right-side aryl moiety. X1 represents two substituents, which may be the same or different, disposed in the 4? and 5? positions on the aryl group, wherein X1 is selected from halogen, alkyl, alkoxy, halogenated alkoxy, hydroxyalkyl, pyrollyl, optionally substituted aryloxy, alkylamino, dialkylamino, carbamyl, amido, alkylamido dialkylamido, acylamino, alkylsulfonylamido, trihalomethoxy, trihalocarbon, thioalkyl, SO2alkyl, COO alkyl, KH2, OH, CN, SO2X5, NO2, NO, C?SR2 NSO2X5, C?OR2, where X5 is F, NH2, alkyl or H, and R2 is alkyl, NH2, NH-alkyl or O-alkyl, C1 to C6 alkyl or alkoxy; or wherein X1 has the formula —O—(CH2)n—O—, wherein n is an integer from O to 2, preferably 1 or 2, and one of the oxygens is bonded at the 5?-position and the other at the 4?-position of the aryl ring. The compounds are useful in cancer therapy and as radioimaging ligands.Type: ApplicationFiled: June 13, 2017Publication date: November 30, 2017Inventors: Gabriela Chiosis, Huazhong He, Laura Llauger-Bufi, Joungnam Kim, Steven M. Larson, Peter Smith-Jones